Meeting
2021 ASCO Annual Meeting
Low-dose metronomic topotecan and pazopanib in children with recurrent or refractory solid tumors: A C17 Canadian phase I trial (TOPAZ).
Authors
Arif Manji
The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Arif Manji , Daniel A. Morgenstern , Yvan Samson , Rebecca Deyell , Donna Johnston , Victor Anthony Lewis , Alexandra Patricia Zorzi , Jason N. Berman , Kathy Brodeur-Robb , Ellen Morrison , Sylvain Baruchel , James A. Whitlock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02303028
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10020)
DOI
10.1200/JCO.2021.39.15_suppl.10020
Abstract #
10020
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
First Author: Eric Schafer
Poster
2013 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
First Author: Sarah Leary
Poster
2023 ASCO Annual Meeting
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.
First Author: Theodore Willis Laetsch
First Author: Stuart Cramer